Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

This trial is testing a combination of two drugs — pacritinib (a JAK2 inhibitor) and talazoparib (a PARP inhibitor) — in patients with myeloproliferative neoplasms (blood cancers like myelofibrosis) who did not respond adequately to a prior JAK2 inhibitor drug. **You may be eligible if...** - You have been diagnosed with myelofibrosis, polycythemia vera, essential thrombocytosis, or related blood disorders - You previously received a JAK2 inhibitor for at least 12 weeks with documented disease progression - You are 18 or older with an adequate performance status (ECOG 0–2) - You have significant disease-related symptoms **You may NOT be eligible if...** - Your disease has transformed into acute myeloid leukemia (more than 20% blasts) - You have a history of hemorrhagic stroke or uncontrolled bleeding - You have HIV and are on antiretroviral therapy - You have uncontrolled serious medical conditions or other active cancers (with limited exceptions) Talk to your doctor to see if this trial is right for you.